The European Commission (EC) and other national competition authorities (NCAs) have traditionally shied away from investigating allegations of excessive pricing and appearing as price regulators. Commissioner Vestager warned...more
4/26/2018
/ Abuse of Dominance ,
Actavis Inc. ,
Antitrust Investigations ,
Court of Justice of the European Union (CJEU) ,
EU ,
Excessive Pricing ,
Hoffman LaRoche ,
Merck ,
Pay-For-Delay ,
Pfizer ,
Pharmaceutical Industry ,
Prescription Drugs ,
Pricing ,
Treaty on the Functioning of the European Union (TFEU) ,
UK ,
UK Competition Appeal Tribunal (CAT)